Michael W Parker
Overview
Explore the profile of Michael W Parker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
259
Citations
6084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kan W, Weekley C, Nero T, Hercus T, Yip K, Tumes D, et al.
Immunol Rev
. 2025 Jan;
329(1):e13430.
PMID: 39748163
Cytokines are small proteins that are critical for controlling the growth and activity of hematopoietic cells by binding to cell surface receptors and transmitting signals across membranes. The β common...
2.
Seneviratne J, Ravindrarajah D, Carter D, Zhai V, Lalwani A, Krishan S, et al.
Cancer Med
. 2024 Nov;
13(21):e70082.
PMID: 39501501
Background: The child cancer, neuroblastoma (NB), is characterised by a low incidence of mutations and strong oncogenic embryonal driver signals. Many new targeted epigenetic modifier drugs have failed in human...
3.
Zeller J, Loseff-Silver J, Khoshmanesh K, Baratchi S, Lai A, Nero T, et al.
Circ Res
. 2024 Oct;
135(11):1033-1047.
PMID: 39421928
Background: CRP (C-reactive protein) is a prototypical acute phase reactant. Upon dissociation of the pentameric isoform (pCRP [pentameric CRP]) into its monomeric subunits (mCRP [monomeric CRP]), it exhibits prothrombotic and...
4.
Cheung B, Mittra R, Murray J, Wang Q, Seneviratne J, Raipuria M, et al.
Commun Biol
. 2024 Oct;
7(1):1322.
PMID: 39402275
MYCN amplification predicts poor prognosis in childhood neuroblastoma. To identify MYCN oncogenic signal dependencies we performed N-ethyl-N-nitrosourea (ENU) mutagenesis on the germline of neuroblastoma-prone TH-MYCN transgenic mice to generate founders...
5.
Ishii K, Hermans S, Georgopoulou M, Nero T, Hancock N, Crespi G, et al.
FEBS J
. 2024 Sep;
291(24):5398-5419.
PMID: 39325669
Human 5'-3' exonuclease PLD3, a member of the phospholipase D family of enzymes, has been validated as a therapeutic target for treating Alzheimer's disease. Here, we have determined the crystal...
6.
Fulford T, Soliman C, Castle R, Rigau M, Ruan Z, Dolezal O, et al.
Nat Immunol
. 2024 Jul;
25(8):1355-1366.
PMID: 39014161
Butyrophilin (BTN) molecules are emerging as key regulators of T cell immunity; however, how they trigger cell-mediated responses is poorly understood. Here, the crystal structure of a gamma-delta T cell...
7.
Abrahamsen H, Sanford T, Collamore C, Johnstone B, Coyne M, Garcia-Bayona L, et al.
Nat Commun
. 2024 Jun;
15(1):5028.
PMID: 38866748
Cholesterol-dependent cytolysins (CDCs) comprise a large family of pore-forming toxins produced by Gram-positive bacteria, which are used to attack eukaryotic cells. Here, we functionally characterize a family of 2-component CDC-like...
8.
Dmello R, Palmieri M, Thilakasiri P, Doughty L, Nero T, Poh A, et al.
Cell Death Dis
. 2024 Apr;
15(4):255.
PMID: 38600086
Excessive STAT3 signalling via gp130, the shared receptor subunit for IL-6 and IL-11, contributes to disease progression and poor survival outcomes in patients with colorectal cancer. Here, we provide evidence...
9.
Bouter Y, Noguerola J, Tucholla P, Crespi G, Parker M, Wiltfang J, et al.
Acta Neuropathol
. 2024 Mar;
147(1):59.
PMID: 38526686
No abstract available.
10.
Faysal K, Walsh J, Renner N, Marquez C, Shah V, Tuckwell A, et al.
Elife
. 2024 Feb;
13.
PMID: 38347802
The HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir, developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use. Here, we investigate the...